多发性硬化症中的特里弗卢诺米德治疗结果:葡萄牙人的现实生活经验
Carla Cecília Nunes1, Pedro Abreu2,3, Filipe Correia4
1Centro Hospitalar e Universitário de Coimbra (CHUC), Coimbra, Portugal.
Brain and neuroscience advances
|July 26, 2023
概括
治疗复发性缓解性多发性硬化症的口服治疗Teriflunomide改善了患者的生活质量,并减少了焦虑和抑郁. 现实数据显示,在两年内,高满意度,持续性和安全性.
科学领域:
- 神经学 神经学
- 临床药理学 临床药理学
- 公共卫生 公共卫生
背景情况:
- 复发性复发性多发性硬化症 (RRMS) 严重影响患者的生活质量 (QoL),原因是身体和认知能力下降.
- 特里弗卢诺米德是一种口服疾病修饰疗法 (DMT),用于RRMS管理.
- 关于特里弗卢诺米德的长期有效性和患者经验的真实数据至关重要.
研究的目的:
- 描述在常规临床实践中用teriflunomide治疗的葡萄牙成年RRMS患者.
- 评估QOL,并发症,治疗有效性,满意度,合规性和安全性.
- 评估两年期间的结果,包括COVID-19大流行.
主要方法:
- TeriLIVE-QoL:一个多中心,非干预,前性队列研究.
- 涉及99名RRMS患者接受了14毫克的特里弗卢诺米德治疗.
- 收集了两年的人口统计,临床,患者报告的结果和不良事件数据.
主要成果:
- 年化复发率在一年后下降;医院焦虑和抑郁量表得分在两年后有所改善.
- 患者满意度高 (高达95.6%),方便性,有效性和整体得分高,显示持续改善.
- 治疗持续率为77%,两年后遵守达到82%. 报告了三起严重的不良事件.
结论:
- 在RRMS患者中,TeriLIVE-QoL证明了teriflunomide在RRMS患者中的实际临床有效性.
- 观察到高治疗满意度,一致的安全性和改善的精神病治疗结果.
- 较高的治疗持久性和遵守性表明,teriflunomide在常规实践中耐受性良好并且有效.
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
174
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
174
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
153
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
153
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
195
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
195
Clinical Trials: Overview
3.0K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
3.0K
Drugs for Treatment of Ulcerative Colitis in IBD
175
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
175


